$INMG 'REAL DD' before the kool-aid turned 3 month old

New Post Public Reply Private Reply Replies (1) Message Board
Rrojarom
1,679
$INMG 'REAL DD' before the kool-aid turned 3 month old syrup...

These are the main on the website http://innovativmedia.com/
If this is what you saw as an investor would you pay $50 to watch or to advertise for you with all these dead and outdated website/channels?

Nightmares in Red, White and Blue , American Grindhouse (http://www.nightmaresinredwhiteandblue.com/) deadlink

Area 51: The Alien Interview film assets (https://www.youtube.com/user/AlienInterviewVideo/feed) 2014

The Alien Interview Channel (http://www.area51thealieninterview.com/) 1997

HPLovecraft.TV 2015

Unproduced projects, Mountains of Madness web series (http://www.mountainsofmadnessmovie.com/) deadlink

Film Finance Project/Wasteland Saints not even listed

Films of Fury (http://www.filmsoffury.com/) 2011

Gameplay (http://gameplaymovie.com/) 2015

Money for Nothing (http://www.moneyfornothingmovie.com/featured-videos/) deadlink

Night of the Living Dead 3D: Reanimation (http://www.nightofthelivingdead3d.com/re-animate.html) 2012

ModRock audio visual (http://www.modrockmusical.com/home/) 2012

Program Search Engine Project (VOD movie guide) redirects

Various other content related assets
(http://www.americangrindhouse.net/) deadlink
(http://cannanet.tv/) coming soon
Film Finance Exchange deadlink
New Broadway Cinema deadlink
Just Smart People deadlink
GGBN (http://www.globalgamingnetwork.net/) 2015

These websites are costing $100k+ a year. "The Company is amortizing its film content assets acquired in July 2015 at 4% annually for the first 5 years and then 16%
annually for the next 5 years. For the Quarter ended June 30, 2017, the Company amortized 1% for a total of $25,000."
https://www.otcmarkets.com/ajax/showFinancial...?id=177179

Trading Symbol: INMG
Exact title and class of securities outstanding: Common Stock Class
CUSIP: 45781H 201
Par or Stated Value: 0.00000001
Total shares authorized: 500,000,000 as of: 8/9/17
Total shares outstanding: 256,724,670 as of: 8/9/17
https://www.otcmarkets.com/ajax/showFinancial...?id=177177

"unaudited financials" $100,000,000 worth to $4,000,000 under Tom

The Series C
Preferred Stock is convertible into Common Stock under certain circumstances at $5.00 per share
https://www.otcmarkets.com/ajax/showFinancial...?id=177179

The Series C Preferred
Stock is convertible into Common Stock at the election of the holder at $.20 per share.
https://www.otcmarkets.com/ajax/showFinancial...?id=177179

Series B why don't the numbers ever change to match if they are being converted?

The Company as of June 30, 2016 had 11,139 shares of Series B Preferred Stock authorized and 8,152 issued and outstanding as 87 were converted into 22,880,000 post-split Common Shares the Quarter. The Series B Preferred Stock is convertible into Common Stock on a basis of 1 Preferred share to 2,500,000 Common shares and is non-dilutive as to stock splits.
http://www.otcmarkets.com/financialReportView...;id=158582

The Company as of September 30, 2016 had 11,139 shares of Series B Preferred Stock authorized and 8,152 issued and outstanding as 3 were converted into 15,000,000 Common Shares the Quarter. The Series B Preferred Stock is convertible into Common Stock on a basis of 1 Preferred share to 2,500,000 Common shares and is non-dilutive as to stock splits.
http://www.otcmarkets.com/financialReportView...;id=162192

The Company as of December 31, 2016 had 11,139 shares of Series B Preferred Stock authorized and 8,132 issued and outstanding as an additional 14 shares were converted into 35,000,000 Common Shares the 4th Quarter of 2016. The Series B Preferred Stock is convertible into Common Stock on a basis of 1 Preferred share to 2,500,000 Common shares and is non-dilutive as to stock splits.
http://www.otcmarkets.com/financialReportView...;id=167410

The Company as of March 31, 2017 had 11,139 shares of Series B Preferred Stock authorized and 8,132 issued and outstanding. The issued and outstanding Series B preferred Stock is subject to a lock up and redemption agreement. The Series B Preferred Stock is convertible into Common Stock on a basis of 1 Preferred share to 2,500,000 Common shares and is non-dilutive as to stock splits. 11 shares were converted into 27,500,000 Common Shares during the 1st Quarter of 2017.
http://www.otcmarkets.com/financialReportView...;id=171675

The Company as of June 30, 2017 had 11,139 shares of Series B Preferred Stock authorized and 8,132 issued and outstanding. The issued and outstanding Series B preferred Stock is subject to a lock up and redemption agreement. The Series B Preferred Stock is convertible into Common Stock on a basis of 1 Preferred share to 2,500,000 Common shares and is non-dilutive as to stock splits. 8 shares were converted into 20,000,000 Common Shares during the 2nd Quarter of 2017.
http://www.otcmarkets.com/financialReportView...;id=177179

87 into 22,880,000 (87 x 2,500,000 = 217,500,000)
3 into 15,000,000 ( 3 x 2,500,000 = 7,500,000)
14 into 35,000,000 (14 x 2,500,000 = 35,000,000)
11 into 27,500,000 (11 x 2,500,000 = 27,500,000)
8 into 20,000,000 ( 8 x 2,500,000 = 20,000,000)

123 into 120,380,000... math isn't right

123 x 2,500,000 is 307,500,000

Demand Brands, Inc. (DMAN) Stock Research Links

DMAN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading